CRIg-Fc suppresses skin inflammation. Though the important contribution of the AP to lupus pathogenesis has been recognized in lupus-prone mice, the apparent non-contribution of the classical pathway to the expression of organ damage in the MRL/lpr mouse is intriguing and unexpected.
propose that CRIg-Fc and other inhibitors of the alternative complement pathway such as anti-factor B antibodies should be considered for the treatment of patients with SLE.